Some behavioral effects of AMPA/kainate receptor agonist and antagonists

Journal of Physiology and Pharmacology

Volumn 48, Issue 3, 1997, Pages 479-488

  Czlonkowska A ^a   Siemiatkowski M ^a   Plaznik A ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

AMPA kainate receptor antagonists; Behavior; Rats; S AMPA

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; DIAZEPAM; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; RAT;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CONFLICT (PSYCHOLOGY); DRINKING BEHAVIOR; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID;

EID: 1842405995     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Willetts J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptors antagonists. TiPs 1990; 11: 423-428.
2. Willetts J, Tokarz ME, Balster RL. Pentobarbital-like effects of N-methyl-D-aspartate antagonists in mice. Life Sci 1991; 48: 1795-1798.
3. Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 1989; 26: 505-525.
4. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-387.
5. Farooqui AA, Horrocks LA. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res Rev 1991; 16: 171-191.
6. Rogawski MA. The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 1992; 44 (3): 279-292.
7. Lalonde R, Cote Ch. Behavioral effects of non-NMDA glutamate receptor antagonists. Neurosci Biobehav Rev 1993; 16: 79-84.
8. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330 (9): 613-622.
9. Jessa M, Nazar M, Bidziński A, Płaźnik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol 1996; 6: 55-61.
10. Lees GJ. Therapeutic potential of AMPA receptors ligands in neurological disorders. CNS Drugs 1996; 5 (1): 51-74.
11. Pellegrino LJ, Pellegrino AS, Cushman AJ. A stereotaxic atlas of the rat brain. Plenum Press, New York, 1967.
12. Płaźnik A, Pałejko W, Nazar M, Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994; 4: 279-292.
13. Stefański R, Pałejko W, Kostowski W, Płaźnik A. The comparison of benzodiazepine derivatives and serotonergic agonists and and antagonists in two animal models of anxiety. Neuropharmacology 1992; 31: 1251-1258.
14. Bruhwyler J. Anxiolytic potential of a microgram dose of chlordiazepoxide in the open field test. Eur J Pharmacol 1990; 187: 547-549.
15. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc Brain Metab Rev 1994; 6: 225-256.
16. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobson P, Honore T. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990; 247: 571-574.
17. Smith SE, Durmuller N, Meldrum BS. The non N-methyl-D-asparate receptor antagonists, GYKI-52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1991; 201: 179-183.
18. Stephens DN. Behavioral pharmacology of AMPA antagonists. Behav Pharmacol 1995; 6: 633.
19. Maj J, Rogóz Z, Skuza G, Jaros T. Some behavioral effects of CNQX and NBQX, AMPA receptor antagonists. Pol J Pharmacol 1995; 47: 269-277.
20. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonists. Pol J Pharmacol 1995; 47: 501-507.
21. Danysz W, Essmann U, Bresink I, Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994; 48: 111-118.
22. Mesches MH, Bianchin M, McGaugh JL. The effects of intra-amygdala infusion of the AMPA receptor antagonist CNQX on retention performance following aversive training. Neurobiol Learning Mem 1996; 66: 324-340.
23. Boldry RC, Kelland MD, Engber TM, Chase TN. NBQX inhibitis AMPA-induced locomotion after injection into the nucleus accumbens. Brain Res 1993; 600: 331-334.
24. Willins DL, Wallace LJ, Miller DD, Uretsky NJ. α-amino-3-hydroksy-5-metylisoxazole-4-propionate/kainate receptor antagonists in the nucleus accumbens and ventral pallidum decreased the hypermobility response to psychostimulant drugs. J Pharmacol Exp Ther 1992; 260(3): 1145-1151.
25. Swedberg MDB, Jacobsen P, Honoré T. Discriminative effects of NBQX. Soc Neurosci 1991; 17: 260.
26. Suzdak PD, Sheardown MJ. Effect of the non-NMDA receptor antagonists, 2,3-dihydro-6-nitro-7-sulfamoylbenzo(f)quinoxaline, on local cerebral glucose uptake in the limbic forebrain. J Neurochem 1993; 61: 1577-1580.
27. Karcz-Kubicha M, Liljequist S. Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur J Pharmacol 1995; 279: 171-177.